The investigation of the relationship between sarcopenia and obesity in diabetes, and arteriosclerotic disease.

The investigation of the relationship between sarcopenia and obesity in diabetes, and arteriosclerotic disease. - sarcopenia with diabetes research

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055820

Enrollment

600

Registered

2024-10-15

Start date

2022-09-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The diabetes who had admitted to the Department of Endocrinology and Metabolism at Dokkyo Medical University Hospital with diabetes treatment from January 1, 2020 to March 31,2023.

Exclusion criteria

Exclusion criteria: 1.Patients whose sarcopenia could not be evaluated during hospitalization 2.Patients who had muscle wasting disease. 3.Patients who have requested refusal to participate in this study

Design outcomes

Primary

Measure	Time frame
The prevalence of sarcopenic obesity in diabetes	—

Secondary

Measure	Time frame
Comprehensively examine the correlation between the following items; Red blood cell count, white blood cell count, white blood cell differential, platelet count, hemoglobin, hematocrit, Total protein, albumin, AST, ALT, gamma GTP, BUN, Cre, estimated GFR (eGFR), glucose, free T3, free T4, TSH, C-peptide, uric acid, BNP, hydroxybutyric acid, LDL cholesterol, HDL cholesterol, triglyceride, HbA1c, Urinary albumin / creatinine rate, L-FABP, urinary glucose, Pulse wave (ABI, CAVI), nerve conduction velocity test, electrocardiogram, CVR-R, Umbilical circumference, grip strength, walking speed (m/sec),In body (body composition meter): Limb skeletal muscle index (SMI), body fat percentage, body fat amount, water content, muscle mass,body weight, BMI, Systolic blood pressure, diastolic blood pressure, pulse rate, Age, gender,Duration of diabetes, stage of retinopathy, presence or absence of neuropathy, stage of nephropathy, stage of CKD, Schellong tests, type of diabetes medication, presence or absence of hypertension, presence or absence of dyslipidemia.	—

Measure

Time frame

Comprehensively examine the correlation between the following items; Red blood cell count, white blood cell count, white blood cell differential, platelet count, hemoglobin, hematocrit, Total protein, albumin, AST, ALT, gamma GTP, BUN, Cre, estimated GFR (eGFR), glucose, free T3, free T4, TSH, C-peptide, uric acid, BNP, hydroxybutyric acid, LDL cholesterol, HDL cholesterol, triglyceride, HbA1c, Urinary albumin / creatinine rate, L-FABP, urinary glucose, Pulse wave (ABI, CAVI), nerve conduction velocity test, electrocardiogram, CVR-R, Umbilical circumference, grip strength, walking speed (m/sec),In body (body composition meter): Limb skeletal muscle index (SMI), body fat percentage, body fat amount, water content, muscle mass,body weight, BMI, Systolic blood pressure, diastolic blood pressure, pulse rate, Age, gender,Duration of diabetes, stage of retinopathy, presence or absence of neuropathy, stage of nephropathy, stage of CKD, Schellong tests, type of diabetes medication, presence or absence of hypertension, presence or absence of dyslipidemia.

—

Countries

Japan

Contacts

Public ContactToshie Iijima

Dokkyo Medical University Hospital Department of Endocrinology and metabolism

toshieo1213@gmail.com0282861111

Outcome results